Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape

GSVA: gene set variation analysis for microarray and RNA-Seq data

Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440

Molecular signatures database (MSigDB) 3.0

Liberzon, A., Subramanian, A., Pinchback, R., Thorvaldsdóttir, H., Tamayo, P., & Mesirov, J. P. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr260 · Cited by 7,111

Cancer immunotherapy using checkpoint blockade

Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400

The EMBL-EBI search and sequence analysis tools APIs in 2019

Madeira, F., Park, Y. M., Lee, J., Buso, N., Gur, T., Madhusoodanan, N., Basutkar, P., Tivey, A. R. N., Potter, S. C., Finn, R. D., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz268 · Cited by 4,167

T cell exhaustion

Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448

Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease

Shull, M. M., Ormsby, I., Kier, A. B., Pawlowski, S., Diebold, R. J., Yin, M., Allen, R., Sidman, C., Proetzel, G., Calvin, D., et al. (1992) · Nature · doi:10.1038/359693a0 · Cited by 2,985

TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851

TGF-β signaling in health, disease and therapeutics

Deng, Z., Fan, T. T., Chu, X., Tian, H., Zheng, Y., Li, C., & He, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01764-w · Cited by 1,360

TGFβ biology in cancer progression and immunotherapy

Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944

Immunotherapy: Reshape the Tumor Immune Microenvironment

Bingzhe, L. V., Wang, Y., Ma, D., Cheng, W., Liu, J., Yong, T., Chen, H., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844142 · Cited by 500

Resistance Mechanisms to Anti-PD Cancer Immunotherapy

Vesely, M. D., Zhang, T., & Chen, L. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-070621-030155 · Cited by 468

Novel therapies emerging in oncology to target the TGF‐β pathway

Kim, B.-G., Malek, E., Choi, S. H., Ignatz-Hoover, J. J., & Driscoll, J. J. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01053-x · Cited by 453

Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors

Lei, Q., Wang, D., Sun, K., Wang, L., & Zhang, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00672 · Cited by 428

Targeting TGFβ signal transduction for cancer therapy

Liu, S., Ren, J., & ten Dijke, P. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00436-9 · Cited by 413

Overcoming TGFβ-mediated immune evasion in cancer

Tauriello, D. V. F., Sancho, E., & Batlle, E. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00413-6 · Cited by 377

TGF ‐β as a driver of fibrosis: physiological roles and therapeutic opportunities

Budi, E. H., Schaub, J. R., Decaris, M. L., Turner, S., & Derynck, R. (2021) · The Journal of Pathology · doi:10.1002/path.5680 · Cited by 310

Neutrophil extracellular traps promote metastasis in gastric cancer patients with postoperative abdominal infectious complications

Xia, X., Zhang, Z., Zhu, C., Ni, B., Wang, S., Yang, S., Yu, F., Zhao, E., Li, Q., & Zhao, G. (2022) · Nature Communications · doi:10.1038/s41467-022-28492-5 · Cited by 220

The immune landscape of neuroblastoma: Challenges and opportunities for novel therapeutic strategies in pediatric oncology

Wienke, J., Dierselhuis, M. P., Tytgat, G. A. M., Künkele, A., Nierkens, S., & Molenaar, J. J. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.11.014 · Cited by 221

Cancer‐associated fibroblasts: Key players in shaping the tumor immune microenvironment

Desbois, M., & Wang, Y. (2021) · Immunological Reviews · doi:10.1111/imr.12982 · Cited by 221

Designing Cancer Immunotherapies That Engage T Cells and NK Cells

Kyrysyuk, O., & Wucherpfennig, K. W. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101921-044122 · Cited by 220

TGFβ-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts

Grauel, A. L., Nguyen, B., Ruddy, D., Laszewski, T., Schwartz, S., Chang, J., Chen, J., Piquet, M., Pelletier, M., Yan, Z., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19920-5 · Cited by 211

TGF-β Signaling and Resistance to Cancer Therapy

Zhang, M., Zhang, Y. Y., Chen, Y., Wang, J., Wang, Q., & Lu, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.786728 · Cited by 204

KRAS drives immune evasion in a genetic model of pancreatic cancer

Ischenko, I., D’Amico, S., Rao, M., Li, J., Hayman, M. J., Powers, S., Petrenko, O., & Reich, N. C. (2021) · Nature Communications · doi:10.1038/s41467-021-21736-w · Cited by 189

Dual inhibition of TGF‐β and PD‐L1: a novel approach to cancer treatment

Gulley, J. L., Schlom, J., Barcellos‐Hoff, M. H., Wang, X., Seoane, J., Audhuy, F., Lan, Y., Dussault, I., & Moustakas, A. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13146 · Cited by 182

TGF-beta signal transduction: biology, function and therapy for diseases

Tie, Y., Tang, F., Peng, D., Zhang, Y., & Shi, H. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00109-9 · Cited by 186

Transforming Growth Factor-β: A Multifunctional Regulator of Cancer Immunity

Xue, V. W., Chung, J. Y., Córdoba, C. A. G., Cheung, A. H. K., Kang, W., Lam, E. W. ‐., Leung, K. T., To, K., Lan, H. Y., & Tang, P. M. (2020) · Cancers · doi:10.3390/cancers12113099 · Cited by 154

Mechano-therapeutics: Targeting Mechanical Signaling in Fibrosis and Tumor Stroma

Tschumperlin, D. J., & Lagares, D. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107575 · Cited by 146

TGFβ control of immune responses in cancer: a holistic immuno-oncology perspective

Nixon, B. G., Gao, S., Wang, X., & Li, M. O. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00796-z · Cited by 144

TGFβ2 and TGFβ3 isoforms drive fibrotic disease pathogenesis

Sun, T., Huang, Z., Liang, W.-C., Yin, J., Lin, W. Y., Wu, J., Vernes, J.-M., Lutman, J., Caplazi, P., Jeet, S., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0407 · Cited by 134

Beyond the Barrier: Unraveling the Mechanisms of Immunotherapy Resistance

Bell, H. N., & Zou, W. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101819-024752 · Cited by 135

Inhibition of NF-κB signaling unveils novel strategies to overcome drug resistance in cancers

Li, Y., Zhao, B., Peng, J., Tang, H., Wang, S., Peng, S., Ye, F., Wang, J., Ouyang, K., Li, J., et al. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2023.101042 · Cited by 135

Targeting immunosuppression by TGF-β1 for cancer immunotherapy

de Streel, G., & Lucas, S. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114697 · Cited by 131

Reactive oxygen species-sensitive polymeric nanocarriers for synergistic cancer therapy

Cao, Z., Li, D., Wang, J., & Yang, X. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.05.023 · Cited by 118

Roles of TGF-β signaling pathway in tumor microenvirionment and cancer therapy

Zhao, H., Wei, J., & Sun, J. M. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107101 · Cited by 118

Synergistic checkpoint-blockade and radiotherapy–radiodynamic therapy via an immunomodulatory nanoscale metal–organic framework

Ni, K., Xu, Z., Culbert, A. A., Luo, T., Guo, N., Yang, K., Pearson, E. A., Preusser, B., Wu, T., Rivière, P. J. L., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00846-w · Cited by 113

Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models

Martínez-Usatorre, A., Kadioglu, E., Boivin, G., Cianciaruso, C., Guichard, A., Torchia, B., Zangger, N., Nassiri, S., Keklikoglou, I., Schmittnaegel, M., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd1616 · Cited by 107

Combined PD-L1/TGFβ blockade allows expansion and differentiation of stem cell-like CD8 T cells in immune excluded tumors

Castiglioni, A., Yang, Y., Williams, K., Gogineni, A., Lane, R. S., Wang, A. W., Shyer, J. A., Zhang, Z., Mittman, S., Gutierrez, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40398-4 · Cited by 104

Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy

Krishnamoorthy, M., Gerhardt, L., & Vareki, S. M. (2021) · Cells · doi:10.3390/cells10051170 · Cited by 99

Immunotherapy for advanced hepatocellular carcinoma, where are we?

Li, Z., Ding, J., Li, H., Wang, Z., & Wu, J. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188441 · Cited by 95

The TGF-β Pathway: A Pharmacological Target in Hepatocellular Carcinoma?

Gonzalez‐Sanchez, E., Vaquero, J., Fernández‐Barrena, M. G., Lasarte, J. J., Avila, M. A., Sarobe, P., Reig, M., Calvo, M., & Fabregat, I. (2021) · Cancers · doi:10.3390/cancers13133248 · Cited by 97

TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy

Yi, M., Li, T., Niu, M., Wu, Y., Zhao, Z., & Wu, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1061394 · Cited by 95

TGFβ-Directed Therapeutics: 2020

Teicher, B. A. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107666 · Cited by 95

Nanovesicles loaded with a TGF-β receptor 1 inhibitor overcome immune resistance to potentiate cancer immunotherapy

Zhou, M., Wang, J., Pan, J., Wang, H., Huang, L., Hou, B., Lai, Y., Wang, F., Guan, Q., Wang, F., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39035-x · Cited by 92

TGF-β signaling networks in the tumor microenvironment

Chan, M. K.-K., Chung, J. Y.-F., Tang, P. C.-T., Chan, A. S.-W., Ho, J. Y.-Y., Lin, T. P.-T., Chen, J., Leung, K.-T., To, K.-F., Lan, H.-Y., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215925 · Cited by 90

Cancer-associated fibroblasts as therapeutic targets for cancer: advances, challenges, and future prospects

Cao, Z., Quazi, S., Arora, S., Osellame, L. D., Burvenich, I. J. G., Janes, P. W., & Scott, A. M. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-024-01099-2 · Cited by 92

TGF-β Signaling in Metastatic Colorectal Cancer (mCRC): From Underlying Mechanism to Potential Applications in Clinical Development

Li, X.-S., Wu, Y., & Tian, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214436 · Cited by 83

The difficulty in translating the preclinical success of combined TGFβ and immune checkpoint inhibition to clinical trial

Metropulos, A. E., Munshi, H. G., & Principe, D. R. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.104380 · Cited by 81

Cancer-associated Fibroblasts in Bladder Cancer: Origin, Biology, and Therapeutic Opportunities

Caramelo, B., Zagorac, S., Corral, S., Marqués, M., & Real, F. X. (2023) · European Urology Oncology · doi:10.1016/j.euo.2023.02.011 · Cited by 81

Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses

Odunsi, K. O., Qian, F., Lugade, A. A., Yu, H., Geller, M. A., Fling, S. P., Kaiser, J. C., Lacroix, A. M., D’Amico, L., Ramchurren, N., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abg8402 · Cited by 80

News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors

Melaiu, O., Lucarini, V., Giovannoni, R., Fruci, D., & Gemignani, F. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.001 · Cited by 76

Therapeutic targeting of TGF-β in cancer: hacking a master switch of immune suppression

van den Bulk, J., de Miranda, N. F. C. C., & ten Dijke, P. (2021) · Clinical Science · doi:10.1042/cs20201236 · Cited by 77

Integrin-αV-mediated activation of TGF-β regulates anti-tumour CD8 T cell immunity and response to PD-1 blockade

Malenica, I., Adam, J., Corgnac, S., Mezquita, L., Auclin, É., Damei, I., Grynszpan, L., Gros, G., de Montpréville, V., Planchard, D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25322-y · Cited by 76

Revisiting the role of cancer-associated fibroblasts in tumor microenvironment

Lan, X., Li, W., Zhao, K., Wang, J., Li, S., & Hai, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1582532 · Cited by 75

The role of LTBPs in TGF beta signaling

Rifkin, D. B., Sachan, N., Singh, K., Sauber, E., Tellides, G., & Ramirez, F. (2021) · Developmental Dynamics · doi:10.1002/dvdy.331 · Cited by 71

Cancer immune exclusion: breaking the barricade for a successful immunotherapy

Bruni, S., Mercogliano, M. F., Mauro, F. L., Russo, R. I. C., & Schillaci, R. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1135456 · Cited by 72

Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities

Yin, N., Li, X., Zhang, X., Xue, S., Cao, Y., Niedermann, G., Lu, Y., & Xue, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01826-z · Cited by 74

Research progress on drugs targeting the TGF-β signaling pathway in fibrotic diseases

Shi, N., Wang, Z., Zhu, H., Liu, W., Zhao, M., Jiang, X., Zhao, J., Ren, C., Zhang, Y., & Luo, L. (2022) · Immunologic Research · doi:10.1007/s12026-022-09267-y · Cited by 71

Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy

Almawash, S. (2025) · Cancers · doi:10.3390/cancers17050880 · Cited by 66

Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy

Tschernia, N. P., & Gulley, J. L. (2022) · BioDrugs · doi:10.1007/s40259-022-00521-1 · Cited by 61

Context-dependent TGFβ family signalling in cell fate regulation

Richardson, L., Wilcockson, S. G., Guglielmi, L., & Hill, C. S. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00638-3 · Cited by 63

Inhibition of integrin αvβ6 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer

Busenhart, P., Montalban‐Arques, A., Katkeviciutė, E., Morsy, Y., Passen, C. V., Hering, L., Atrott, K., Lang, S., Garzon, J. F. G., Naschberger, E., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003465 · Cited by 59

CAF-immune cell crosstalk and its impact in immunotherapy

Maia, A. R. R., Schöllhorn, A., Schuhmacher, J., & Gouttefangeas, C. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00977-x · Cited by 59

TGF-β signaling pathway: Therapeutic targeting and potential for anti-cancer immunity

Ali, S., Rehman, M. U., Yatoo, A. M., Arafah, A. M., Khan, A., Rashid, S., Majid, S., Ali, A., & Ali, M. N. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175678 · Cited by 60

Exploring TGF-β Signaling in Cancer Progression: Prospects and Therapeutic Strategies

Sheikh, K., Amjad, M., Irfan, M., Anjum, S., Majeed, T., Riaz, M. U., Jassim, A. Y., Sharif, E., & Ibrahim, W. N. (2025) · OncoTargets and Therapy · doi:10.2147/ott.s493643 · Cited by 61

Pro-tumor γδ T Cells in Human Cancer: Polarization, Mechanisms of Action, and Implications for Therapy

Chabab, G., Barjon, C., Bonnefoy, N., & Lafont, V. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02186 · Cited by 58

Tumor Microenvironment and Hydrogel-Based 3D Cancer Models for In Vitro Testing Immunotherapies

Vitale, C., Marzagalli, M., Scaglione, S., Dondero, A., Bottino, C., & Castriconi, R. (2022) · Cancers · doi:10.3390/cancers14041013 · Cited by 56

Long Noncoding RNAs Control the Modulation of Immune Checkpoint Molecules in Cancer

Xu, S., Wang, Q., Kang, Y., Liu, J., Yin, Y., Liu, L., Wu, H., Li, S., Sui, S., Shen, M., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0696 · Cited by 52

Advances and Challenges in Targeting TGF-β Isoforms for Therapeutic Intervention of Cancer: A Mechanism-Based Perspective

Danielpour, D. (2024) · Pharmaceuticals · doi:10.3390/ph17040533 · Cited by 58

Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies

Ngiow, S. F., & Young, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01633 · Cited by 51

Exosome-mediated delivery of transforming growth factor-β receptor 1 kinase inhibitors and toll-like receptor 7/8 agonists for combination therapy of tumors

Lee, J. H., Song, J., Kim, I. G., You, G., Kim, H., Ahn, J., & Mok, H. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.01.005 · Cited by 51

Recent Advances in the Development of TGF-β Signaling Inhibitors for Anticancer Therapy

Lee, H.-J. (2020) · Journal of Cancer Prevention · doi:10.15430/jcp.2020.25.4.213 · Cited by 49

Comprehensive review of the resistance mechanisms of colorectal cancer classified by therapy type

Oh, J. M., Kim, S. W., Tsung, C., Kent, E. W., Jain, A., Ruff, S. M., & Zhang, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1571731 · Cited by 50

Cancer Cell Phenotype Plasticity as a Driver of Immune Escape in Melanoma

Benboubker, V., Boivin, F., Dalle, S., & Caramel, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.873116 · Cited by 51

Immunotherapy resistance in solid tumors: mechanisms and potential solutions

Lefler, D. S., Manobianco, S. A., & Bashir, B. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2315655 · Cited by 49

Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discoveryPreprint

Cuccarese, M. F., Earnshaw, B. A., Heiser, K., Fogelson, B., Davis, C. T., McLean, P., Gordon, H. B., Skelly, K.-R., Weathersby, F. L., Rodic, V., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.02.233064 · Cited by 48

TGFβ receptor inhibition unleashes interferon-β production by tumor-associated macrophages and enhances radiotherapy efficacy

Hamon, P., de Thoré, M. G., Classe, M., Signolle, N., Liu, W., Bawa, O., Meziani, L., Clémenson, C., Milliat, F., Deutsch, É., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003519 · Cited by 51

The Love-Hate Relationship Between TGF-β Signaling and the Immune System During Development and Tumorigenesis

Chen, B., Mu, C., Zhang, Z., He, X., & Liu, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.891268 · Cited by 46

Cuproptosis status affects treatment options about immunotherapy and targeted therapy for patients with kidney renal clear cell carcinoma

Zhang, G., Chen, X., Fang, J., Tai, P., Chen, A., & Cao, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.954440 · Cited by 47

Rebalancing TGFβ1/BMP signals in exhausted T cells unlocks responsiveness to immune checkpoint blockade therapy

Saadey, A. A., Yousif, A., Osborne, N., Shahinfar, R., Chen, Y., Laster, B., Rajeev, M., Bauman, P., Webb, A., & Ghoneim, H. E. (2022) · Nature Immunology · doi:10.1038/s41590-022-01384-y · Cited by 47

Exploiting protease activation for therapy

Bleuez, C., Koch, W. F., Urbach, C., Hollfelder, F., & Jermutus, L. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.03.011 · Cited by 45

SMAD7 expression in CAR-T cells improves persistence and safety for solid tumors

Liang, S., Zheng, R., Zuo, B., Li, J., Wang, Y., Han, Y., Dong, H., Zhao, X., Zhang, Y., Wang, P., et al. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01120-y · Cited by 42

Therapeutic targeting of TGF ‐β in lung cancer

Aftabi, S., Behrooz, A. B., Cordani, M., Rahiman, N., Sadeghdoust, M., Aligolighasemabadi, F., Pistorius, S., Alavizadeh, S. H., Taefehshokr, N., & Ghavami, S. (2024) · FEBS Journal · doi:10.1111/febs.17234 · Cited by 42

Activation of the DDR Pathway Leads to the Down-Regulation of the TGFβ Pathway and a Better Response to ICIs in Patients With Metastatic Urothelial Carcinoma

Zhou, C., Lin, A., Cao, M., Ding, W., Mou, W., Guo, N., Chen, Z., Zhang, J., & Luo, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.634741 · Cited by 42

Natural Products in Preventing Tumor Drug Resistance and Related Signaling Pathways

Yang, C., Mai, Z., Liu, C., Yin, S., Cai, Y., & Xia, C. (2022) · Molecules · doi:10.3390/molecules27113513 · Cited by 41

68Ga-FAPI PET imaging monitors response to combined TGF-βR inhibition and immunotherapy in metastatic colorectal cancer

Li, K., Liu, W., Yu, H., Chen, J., Tang, W., Wang, J., Qi, M., Sun, Y., Xu, X., Zhang, J., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci170490 · Cited by 40

Signaling pathways in colorectal cancer: implications for the target therapies

Song, Y., Chen, M., Wei, Y., Ma, X., & Shi, H. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00178-y · Cited by 42

ASCL2 induces an immune excluded microenvironment by activating cancer-associated fibroblasts in microsatellite stable colorectal cancer

Zhang, D., Ni, Q.-Q., Liang, Q.-Y., He, L.-L., Qiu, B.-W., Zhang, L.-J., Mou, T., Le, C., Huang, Y., Li, T., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02806-3 · Cited by 37

Resistance to immune checkpoint inhibitors in gastric cancer

Liu, K., Yuan, S., Wang, C., & Zhu, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1285343 · Cited by 36

The incorporation of acetylated LAP-TGF-β1 proteins into exosomes promotes TNBC cell dissemination in lung micro-metastasis

Yu, P., Han, Y., Meng, L., Tang, Z., Jin, Z., Zhang, Z., Zhou, Y., Luo, J. F., Luo, J., Han, C. Q., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01995-z · Cited by 35

Cancer-Associated Fibroblasts Facilitate Squamous Cell Carcinoma Lung Metastasis in Mice by Providing TGFβ-Mediated Cancer Stem Cell Niche

Shi, X., Luo, J., Weigel, K. J., Hall, S. C., Du, D., Wu, F., Rudolph, M. C., Zhou, H., Young, C. D., & Wang, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.668164 · Cited by 35

Combined mitoxantrone and anti-TGFβ treatment with PD-1 blockade enhances antitumor immunity by remodelling the tumor immune landscape in neuroblastoma

Lucarini, V., Melaiu, O., D’Amico, S., Pastorino, F., Tempora, P., Scarsella, M., Pezzullo, M., Ninno, A. D., Doria, V., Cilli, M., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02525-9 · Cited by 36

Hyperprogression, a challenge of PD-1/PD-L1 inhibitors treatments: potential mechanisms and coping strategies

Zhao, L.-P., Hu, J.-H., Hu, D., Wang, H., Huang, C.-G., Luo, R., Huang, X., Huang, X., Xie, T., & Lou, J.-S. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112949 · Cited by 34

Autophagy orchestrates resistance in hepatocellular carcinoma cells

Seydi, H., Nouri, K., Rezaei, N., Tamimi, A., Hassan, M., Mirzaei, H., & Vosough, M. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114487 · Cited by 33

TIM-3 Expression and M2 Polarization of Macrophages in the TGFβ-Activated Tumor Microenvironment in Colorectal Cancer

Katagata, M., Okayama, H., Nakajima, S., Saito, K., Sato, T., Sakuma, M., Fukai, S., Endo, E., Sakamoto, W., Saito, M., et al. (2023) · Cancers · doi:10.3390/cancers15204943 · Cited by 31

TGF-β inhibition can overcome cancer primary resistance to PD-1 blockade: A mathematical model

Siewe, N., & Friedman, A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0252620 · Cited by 33

A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance

Santiago-Sánchez, G. S., Fabian, K. P., & Hodge, J. W. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2308097 · Cited by 31

Combinatorial Immunotherapies for Metastatic Colorectal Cancer

Janssen, E., Subtil, B., Ortiz, F. D. L. J., Verheul, H. M. W., & Tauriello, D. V. F. (2020) · Cancers · doi:10.3390/cancers12071875 · Cited by 31

Neutrophils: Musketeers against immunotherapy

Zahid, K. R., Raza, U., Tumbath, S., Jiang, L., Xu, W., & Huang, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.975981 · Cited by 31

TGFβ Antagonizes IFNγ-Mediated Adaptive Immune Evasion via Activation of the AKT–Smad3–SHP1 Axis in Lung Adenocarcinoma

Ye, F., Cai, Z., Wang, B., Zeng, C., Xi, Y., Hu, S., Qu, R., Yuan, Z., Yue, J., Tian, Y., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3009 · Cited by 30

Preclinical development and clinical studies of targeted JAK/STAT combined Anti-PD-1/PD-L1 therapy

Chen, M., & Wang, S.-L. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111717 · Cited by 29

An antibody that inhibits TGF-β1 release from latent extracellular matrix complexes attenuates the progression of renal fibrosis

Jackson, J., Streich, F. C., Pal, A., Coricor, G., Boston, C., Brueckner, C., Canonico, K., Chapron, C., Cote, S. M., Dagbay, K. B., et al. (2024) · Science Signaling · doi:10.1126/scisignal.adn6052 · Cited by 30

Identification of an Immune-Related Gene Signature Based on Immunogenomic Landscape Analysis to Predict the Prognosis of Adult Acute Myeloid Leukemia Patients

Zhu, R., Tao, H., Lin, W., Tang, L. V., & Hu, Y. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.574939 · Cited by 29

TGFβ: Signaling Blockade for Cancer Immunotherapy

Chen, S., Mamaï, O., & Akhurst, R. J. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070620-103554 · Cited by 29

Expression, regulation, and function of PD-L1 on non-tumor cells in the tumor microenvironment

Hu, L., Sun, C., Yuan, K., & Yang, P. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104181 · Cited by 27

Simultaneous blockage of contextual TGF-β by cyto-pharmaceuticals to suppress breast cancer metastasis

Li, Y., Hu, Q., Li, W., Liu, S., Li, K., Li, X., Du, J., Yu, Z., Wang, C., & Zhang, C. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.06.012 · Cited by 27

Strategies for Improving the Efficacy of CAR T Cells in Solid Cancers

Kyte, J. A. (2022) · Cancers · doi:10.3390/cancers14030571 · Cited by 26

Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy

Liu, J., Tao, H., Yuan, T., Li, J., Li, J., Liang, H., Huang, Z., & Zhang, E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.992611 · Cited by 27

Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors

Welsh, B. T., Faucette, R., Bilic, S., Martin, C. J., Schürpf, T., Chen, D. J., Nicholls, S. B., Lansita, J. A., & Kalra, A. V. (2021) · International Journal of Toxicology · doi:10.1177/1091581821998945 · Cited by 28

Abstract 4090: Defeating primary checkpoint resistance: SRTβ1-Ab3 is a first-in-class, fully human antibody that renders resistant tumors sensitive to anti-PD-1

Schürpf, T., Martin, C. J., Littlefield, C., Chapron, C., Wawersik, S., Kalra, A. V., Simpson, A., Danehy, F. T., Boston, C., Nikiforov, A., et al. (2019) · Immunology · doi:10.1158/1538-7445.sabcs18-4090

TGFβ1-specific antibody spurs anti-tumour immunity

Cully, M. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00058-4 · Cited by 2

773 SOF10, selectively blocking latent TGF-β1 activation, potentiates the efficacy of checkpoint blockade therapy by modulating CAF dynamics and T cell infiltration

Sato, I., Kanamori, M., Nakagawa, K., Sun, S., Asanuma, K., Kawauchi, H., Kayukawa, Y., Matsuo, S., Shida-Kawazoe, M., Kashiwagi, D., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-sitc2024.0773 · Cited by 1

First-in-human phase 1 trial (DRAGON) of SRK-181, a potential first-in-class selective latent TGFβ1 inhibitor, alone or in combination with anti-PD-(L)1 treatment in patients with advanced solid tumors.

Yap, T. A., Barve, M. A., Gainor, J. F., Weekes, C. D., Bockorny, B., Ju, Y., Faucette, R., Bilic, S., Lee-Hoeflich, S. T., Song, G., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.tps3146 · Cited by 7